Characterization of metabolites of larotaxel in rat by liquid chromatography coupled with Q exactive high-resolution benchtop quadrupole orbitrap mass spectrometer

References

• Ahn HK, Jung M, Sym SJ, et al. (2014). A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol 74:277–82
   PubMed Web of Science ®Google Scholar
• Bardelmeijer HA, Roelofs AB, Hillebrand MJ, et al. (2005). Metabolism of docetaxel in mice. Cancer Chemother Pharmacol 56:299–306
   PubMed Web of Science ®Google Scholar
• Bessonneau V, Bojko B, Azad A, et al. (2014). Determination of bronchoalveolar lavage bile acids by solid phase microextraction liquid chromatography-tandem mass spectrometry in combination with metabolite profiling: comparison with enzymatic assay. J Chromatogr A 1367:33–8
   PubMed Web of Science ®Google Scholar
• Carlsson H, Von Stedingk H, Nilsson U, Tornqvist M. (2014). LC-MS/MS screening strategy for unknown adducts to N-terminal valine in hemoglobin applied to smokers and nonsmokers. Chem Res Toxicol 27:2062–70
   PubMed Web of Science ®Google Scholar
• Che X, Shen L, Xu H, Liu K. (2011). Isolation and characterization of process-related impurities and degradation products in larotaxel. J Pharm Biomed Anal 55:1190–6
   PubMed Web of Science ®Google Scholar
• Clissold SP. (1986). Paracetamol and phenacetin. Drugs 32 Suppl 4:46–59
   PubMed Web of Science ®Google Scholar
• Cresteil T, Monsarrat B, Alvinerie P, et al. (1994). Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res 54:386–92
   PubMed Web of Science ®Google Scholar
• Dahmane E, Boccard J, Csajka C, et al. (2014). Quantitative monitoring of tamoxifen in human plasma extended to 40 metabolites using liquid-chromatography high-resolution mass spectrometry: new investigation capabilities for clinical pharmacology. Anal Bioanal Chem 406:2627–40
   PubMed Web of Science ®Google Scholar
• Frapolli R, Marangon E, Zaffaroni M, et al. (2006). Pharmacokinetics and metabolism in mice of IDN 5390 (13-(N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III), a new oral c-seco-taxane derivative with antiangiogenic property effective on paclitaxel-resistant tumors. Drug Metab Dispos 34:2028–35
   PubMed Web of Science ®Google Scholar
• Fura A, Shu YZ, Zhu M, et al. (2004). Discovering drugs through biological transformation: role of pharmacologically active metabolites in drug discovery. J Med Chem 47:4339–51
   PubMed Web of Science ®Google Scholar
• Karavasilis V, Kosmidis P, Syrigos KN, et al. (2014). Docetaxel and intermittent erlotinib in patients with metastatic Non-Small Cell Lung Cancer; a phase II study from the Hellenic Cooperative Oncology Group. Anticancer Res 34:5649–55
   PubMed Web of Science ®Google Scholar
• Kurata T, Shimada Y, Tamura T, et al. (2000). Phase I and pharmacokinetic study of a new taxoid, RPR 109881A, given as a 1-hour intravenous infusion in patients with advanced solid tumors. J Clin Oncol 18:3164–71
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhang L, Ju P, et al. (2014). Determination of larotaxel and its metabolites in rat plasma by liquid chromatography-tandem mass spectrometry: application for a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 947–948:132–8
   PubMed Web of Science ®Google Scholar
• Ly VT, Caceres-Cortes J, Zhang D, et al. (2009). Metabolism and excretion of an oral taxane analog, [14C]3′-tert-butyl-3′-N-tert-butyloxycarbonyl-4-deacetyl-3′-dephenyl-3′-N-debenzo yl-4-O-methoxy-paclitaxel (BMS-275183), in rats and dogs. Drug Metab Dispos 37:1115–28
   PubMed Web of Science ®Google Scholar
• Martin M, Pienkowski T, Mackey J, Breast Cancer International Research Group, I, et al. (2005). Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302–13
   PubMed Web of Science ®Google Scholar
• Meeves SG, Appajosyula S. (2003). Efficacy and safety profile of fexofenadine HCl: a unique therapeutic option in H1-receptor antagonist treatment. J Allergy Clin Immunol 112:S69–77
   PubMedGoogle Scholar
• Men L, Lin H, Zhao Y, et al. (2014a). Metabolism of TM-2, a potential antitumor drug, in rats by using LC-MS. J Sep Sci 37:625–9
   PubMed Web of Science ®Google Scholar
• Men L, Zhao Y, Lin H, et al. (2014b). Characterization of in vitro metabolites of TM-2, a potential antitumor drug, in rat, dog and human liver microsomes using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 28:2162–70
   PubMed Web of Science ®Google Scholar
• Metzger-Filho O, Moulin C, De Azambuja E, Ahmad A. (2009). Larotaxel: broadening the road with new taxanes. Expert Opin Investig Drugs 18:1183–9
   PubMed Web of Science ®Google Scholar
• Murdoch D, Goa KL, Keam SJ. (2003). Desloratadine: an update of its efficacy in the management of allergic disorders. Drugs 63:2051–77
   PubMed Web of Science ®Google Scholar
• Nicol E, Genty C, Bouchonnet S, Bourcier S. (2015). Structural elucidation of metolachlor photoproducts by liquid chromatography/high-resolution tandem mass spectrometry. Rapid Commun Mass Spectrom 29:2279–86
   PubMed Web of Science ®Google Scholar
• Noh K, Kim DH, Shin BS, et al. (2014). Simultaneous determination of 7-O-succinyl macrolactin A and its metabolite macrolactin A in rat plasma using liquid chromatography coupled to tandem mass spectrometry. J Pharm Biomed Anal 98:85–9
   PubMed Web of Science ®Google Scholar
• Paredes RM, Quinones M, Marballi K, et al. (2014). Metabolomic profiling of schizophrenia patients at risk for metabolic syndrome. Int J Neuropsychopharmacol 17:1139–48
   PubMed Web of Science ®Google Scholar
• Pivot X, Koralewski P, Hidalgo JL, et al. (2008). A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 19:1547–52
   PubMed Web of Science ®Google Scholar
• Racamonde I, Rodil R, Quintana JB, et al. (2014). Determination of benzodiazepines, related pharmaceuticals and metabolites in water by solid-phase extraction and liquid-chromatography-tandem mass spectrometry. J Chromatogr A 1352:69–79
   PubMed Web of Science ®Google Scholar
• Rahman A, Korzekwa KR, Grogan J, et al. (1994). Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 54:5543–6
   PubMed Web of Science ®Google Scholar
• Royer I, Monsarrat B, Sonnier M, et al. (1996). Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res 56:58–65
   PubMed Web of Science ®Google Scholar
• Shou M, Martinet M, Korzekwa KR, et al. (1998). Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 8:391–401
   PubMedGoogle Scholar
• Sottani C, Colombo T, Zucchetti M, et al. (2001). High-performance liquid chromatography/tandem mass spectrometry for the quantitative analysis of a novel taxane derivative (BAY59-8862) in biological samples and characterisation of its metabolic profile in rat bile samples. Rapid Commun Mass Spectrom 15:1807–16
   PubMed Web of Science ®Google Scholar
• Sparreboom A, Van Tellingen O, Scherrenburg EJ, et al. (1996). Isolation, purification and biological activity of major docetaxel metabolites from human feces. Drug Metab Dispos 24:655–8
   PubMed Web of Science ®Google Scholar
• Tolaney SM, Barry WT, Dang CT, et al. (2015). Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 372:134–41
   PubMed Web of Science ®Google Scholar
• Vaclavikova R, Soucek P, Svobodova L, et al. (2004). Different in vitro metabolism of paclitaxel and docetaxel in humans, rats, pigs, and minipigs. Drug Metab Dispos 32:666–74
   PubMed Web of Science ®Google Scholar
• Wang J, Gardinali PR. (2014). Identification of phase II pharmaceutical metabolites in reclaimed water using high resolution benchtop Orbitrap mass spectrometry. Chemosphere 107:65–73
   PubMed Web of Science ®Google Scholar
• Zhang D, Ly VT, Lago M, et al. (2009). CYP3A4-mediated ester cleavage as the major metabolic pathway of the oral taxane 3′-tert-butyl-3′-N-tert-butyloxycarbonyl-4-deacetyl-3′-dephenyl-3′-N-debenzoyl-4-O-methoxycarbonyl-paclitaxel (BMS-275183). Drug Metab Dispos 37:710–18
   PubMed Web of Science ®Google Scholar